Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
đ¤ 5063
đĽ 55
đ 353
Editorial team of Nature Reviews Drug Discovery www.nature.com/nrd
Trends in the landscape of clinical trials of innovative drugs in China since 2015
www.nature.com/articles/d41...
This analysis highlights how China has become a high-volume destination for clinical trials in the past decade, driven by regulatory modernization and capital investment
loading . . .
Trends in the landscape of clinical trials of innovative drugs in China since 2015
Discover the worldâs best science and medicine | Nature.com
https://www.nature.com/articles/d41573-026-00081-x
1 day ago
0
1
0
reposted by
Nature Reviews Drug Discovery
REMEDi4ALL
9 days ago
A new article in Nature Reviews Drug Discovery, inspired by discussions at previous International Drug Repurposing Conferences (iDR), explores how we can make the most of the potential of drug repurposing. đ Read the article:
https://bit.ly/4eyNFjq
đď¸ Register for iDR26: remedi4all.org/iDR26
loading . . .
0
3
2
The evolving landscape of obesity pharmacotherapy
www.nature.com/articles/s41...
rdcu.be/fiw7g
This new Review covers the evolution of obesity pharmacotherapy from GLP1 receptor agonists to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
loading . . .
The evolving landscape of obesity pharmacotherapy - Nature Reviews Drug Discovery
Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...
https://www.nature.com/articles/s41573-026-01427-1
3 days ago
0
3
1
Bloodâbrain barrier (BBB) dysfunction is a hallmark of many diseases of the brain, such as Alzheimer disease. This Review in the May issue covers strategies for BBB repair and protection in various diseases and during normal ageing
rdcu.be/fij4F
www.nature.com/articles/s41...
4 days ago
0
1
1
The ovarian cancer drug market
www.nature.com/articles/d41...
This new article analyses the pipeline of drugs in development for ovarian cancer, such as antibody-drug conjugates, and their expected impact on the market
loading . . .
The ovarian cancer drug market
Discover the worldâs best science and medicine | Nature.com
https://www.nature.com/articles/d41573-026-00077-7
5 days ago
0
1
0
reposted by
Nature Reviews Drug Discovery
Craig M. Crews
8 days ago
First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions
www.nature.com/articles/d41...
loading . . .
First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions
Discover the worldâs best science and medicine | Nature.com
https://www.nature.com/articles/d41573-026-00078-6
0
130
37
Our May issue is live! Read about biologic targeted protein degraders, strategies for blood-brain barrier rejuvenation and repair, targeting extrachromosomal DNA in cancer, therapeutic targeting of neuroimmune mechanisms in neurodegeneration and more here
nature.com/nrd/volumes/...
9 days ago
0
3
0
For readers interested in drug repurposing, this Review evaluates computational approaches to drug repurposing based on categorization of available resources into an online catalogue
www.nature.com/articles/s41...
rdcu.be/fhe2Z
10 days ago
0
2
1
Bridging boundaries: making drug repurposing the new normal
nature.com/articles/d41...
This new article discusses approaches to overcoming systemic challenges in drug repurposing, enabling the approach to contribute more to new therapies, especially for rare diseases
10 days ago
0
0
0
Shifts in pharmaâs therapeutic area focus
www.nature.com/articles/d41...
This new article analyses the evolution of the therapeutic area focus of large pharmaceutical companies, as well as phase III resourcing and the composition of drug launches
11 days ago
1
3
0
Sarah Crunkhorn, Senior Editor at Nature Reviews Drug Discovery, will be attending the TIDES conference on oligonucleotide and peptide therapeutics in Boston on 11-14 May
informaconnect.com/tides/
#TIDESUSA
loading . . .
TIDES USA 2026: Oligonucleotide and Peptide Therapeutics
Join TIDES USA 2026 in Boston, May 11-14, the leading event to accelerate oligo, peptide & mRNA therapeutics to market with leading R&D, manufacturing and CMC strategy insights.
https://informaconnect.com/tides/
15 days ago
0
1
0
The landscape for therapeutic cancer vaccines
www.nature.com/articles/d41...
This new article analyses the pipeline of clinical-stage therapeutic cancer vaccines, including the technology platforms, antigen selection and personalization approaches
loading . . .
The landscape for therapeutic cancer vaccines
Discover the worldâs best science and medicine | Nature.com
https://www.nature.com/articles/d41573-026-00063-z
15 days ago
0
2
1
Tumour-agnostic kinase inhibitors
nature.com/articles/s41...
rdcu.be/fgiHN
For readers interested in kinase inhibitors, this Review covers small-molecule inhibitors that target kinase pathway aberrations as tumourâagnostic agents
loading . . .
Tumour-agnostic kinase inhibitors - Nature Reviews Drug Discovery
Multiple tumour-agnostic kinase inhibitors have been approved that are clinically effective regardless of tumour location. This Review describes the origins of tumour-agnostic drug development, focusi...
https://nature.com/articles/s41573-025-01147-y
16 days ago
0
2
0
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
rdcu.be/fgg49
nature.com/articles/s41...
This new Review covers the expanding toolkit for kinase modulation, such as allosteric modulators and molecular glues
loading . . .
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
Nature Reviews Drug Discovery - Kinases represent one of the largest superfamilies of drug targets, but many members have remained notoriously challenging to drug by traditional small-molecule...
https://rdcu.be/fgg49
16 days ago
0
4
1
reposted by
Nature Reviews Drug Discovery
Acquired Resistance to Therapy Network (ARTNet)
17 days ago
New review just out: Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of
@roswellpark.bsky.social
outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types.
#CDK
#BreastCancer
add a skeleton here at some point
0
1
3
For readers interested in advances with JAK inhibitors, this review in our April issue covers their application in immunological and haematological diseases, as well as the development of inhibitors of the downstream STAT family
rdcu.be/ff5J9
www.nature.com/articles/s41...
loading . . .
Pharmacological targeting of the JAKâSTAT pathway: new concepts and emerging indications
Nature Reviews Drug Discovery - The Janus kinase (JAK)âsignal transducer and activator of transcription (STAT) pathway mediates cellular responses to cytokines and growth factors, and its...
https://rdcu.be/ff5J9
17 days ago
0
5
3
reposted by
Nature Reviews Drug Discovery
Dominic Tyer
18 days ago
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics, whose lead asset is a phase I oral once-daily Type II JAK2 inhibitor
www.pharmaceutical-technology.com/news/eli-lil...
#pharma
loading . . .
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics - Pharmaceutical Technology
Ajaxâs lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.
https://www.pharmaceutical-technology.com/news/eli-lilly-outlays-2-3bn-to-acquire-blood-cancer-specialist-ajax-therapeutics/
0
0
1
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
www.nature.com/articles/s41...
rdcu.be/ffR0W
This new Review discusses how combination strategies, novel CDK2- and CDK4-selective inhibitors and biomarkers are addressing drug resistance and expanding therapeutic uses
loading . . .
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond - Nature Reviews Drug Discovery
Ten years after the first FDA approval, CDK inhibition is entering a new phase in oncology. This Review examines how combination strategies, emerging CDK2- and CDK4-selective inhibitors, and developin...
https://www.nature.com/articles/s41573-026-01431-5
18 days ago
0
4
2
For readers interested in wearable technologies in clinical trials for drug development, this Review discusses the characteristics of different classes of wearable technologies and analyses their use in drug trials
rdcu.be/e9L7x
nature.com/articles/s41...
loading . . .
Wearable technologies in clinical trials for drug development: trends and emerging opportunities
Nature Reviews Drug Discovery - Wearable technologies, which provide new tools to capture physiological and behavioural endpoints in real-world settings, are increasingly being integrated into...
https://rdcu.be/e9L7x
19 days ago
0
0
1
For readers interested in the potential of in vivo CAR T therapies for cancer and autoimmune diseases, here's a comprehensive review
rdcu.be/ffE1i
nature.com/articles/s41...
loading . . .
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug Discovery - In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo...
https://rdcu.be/ffE1i
19 days ago
0
4
1
In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion
www.nature.com/articles/d41...
The deal is the biggest to date in the red-hot race to develop therapies that reprogram immune cells directly in patients for the treatment of cancer and autoimmune diseases
19 days ago
0
1
0
Systemic lupus erythematosus is one autoimmune disease for which CAR-T cell therapies have shown substantial promise in clinical trials. Find out more about therapeutic advances for lupus in this comprehensive review
rdcu.be/ffcqI
www.nature.com/articles/s41...
loading . . .
Advances in the treatment of systemic lupus erythematosus
Nature Reviews Drug Discovery - Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations. This Review discusses advances in understanding its...
https://rdcu.be/ffcqI
22 days ago
0
3
0
For readers interested in the promise and challenges for CAR-T cell therapies for autoimmune diseases, here's a comprehensive review from our April issue
www.nature.com/articles/s41...
loading . . .
Roads and detours for CAR T cell therapy in autoimmune diseases - Nature Reviews Drug Discovery
Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the precl...
https://www.nature.com/articles/s41573-025-01349-4
23 days ago
0
3
0
Realizing the promise of CAR-T cell therapies for autoimmune diseases
www.nature.com/articles/d41...
CAR-T cell therapies that deplete B cells could change the treatment paradigm in B cell-driven autoimmune diseases. This article discusses key considerations in realizing their potential
23 days ago
0
1
0
Biologic degraders push forward in the clinic
www.nature.com/articles/d41...
Antibody-based extracellular targeted protein degraders are advancing in the clinic, highlighting emerging opportunities to destroy disease-linked proteins in cancer and autoimmunity
24 days ago
0
3
0
Safety considerations for cereblon-recruiting targeted protein degraders
rdcu.be/feDVy
www.nature.com/articles/s41...
Degradation of unintended neosubstrates of cereblon is a key safety concern for PROTACs and molecular glues. This new Perspective discusses how to approach it
loading . . .
Safety considerations for cereblon-recruiting targeted protein degraders
Nature Reviews Drug Discovery - Targeted protein degraders that recruit the E3 ligase CRBN are showing promise for challenging drug targets but can have unintended consequences on cellular...
https://rdcu.be/feDVy
25 days ago
0
2
1
Target identification and assessment in the era of AI
rdcu.be/fep9Z
www.nature.com/articles/s41...
This new Review analyses advances in applying AI-driven approaches for therapeutic target exploration, and discusses how to address challenges and limitations in the field
26 days ago
0
3
1
This Review in the April issue covers promising drug targets for schizophrenia treatment that affect neurotransmitter systems, immune processes and inflammation
rdcu.be/fdZNP
www.nature.com/articles/s41...
29 days ago
0
3
0
FDA new drug approvals in Q1 2026
nature.com/articles/d41...
Potential blockbusters approved in the first quarter include an oral IL-23 receptor inhibitor for psoriasis and a glucocorticoid receptor antagonist for various cancers
about 1 month ago
0
2
0
Where are the womenâs health drugs?
www.nature.com/articles/d41...
Wendy Young, an advisor at Google Ventures and former head of small-molecule drug discovery at Genentech, discusses the dearth of womenâs health drug discovery programmes
about 1 month ago
0
5
1
Amorphous solid dispersions and lipid-based formulations could help address delivery challenges for novel therapeutic modalities such as PROTACs and cyclic peptides - find out more about these formulation approaches here
www.nature.com/articles/s41...
rdcu.be/fdqdn
loading . . .
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs - Nature Reviews Drug Discovery
The oral delivery of small-molecule drugs with poor aqueous solubility represents an ongoing drug development challenge. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have eme...
https://www.nature.com/articles/s41573-026-01407-5
about 1 month ago
0
1
1
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
www.nature.com/articles/d41...
Bioconjugated oligonucleotides (BCOs) could expand the applicability of RNA-based drugs. This article presents recommendations when advancing BCOs into the clinic
about 1 month ago
0
2
0
Developing disease-modifying drugs for osteoarthritis has been particularly challenging. Find out about progress with the pipeline in this news article in the April issue
www.nature.com/articles/d41...
about 1 month ago
1
1
0
Our April issue is live! Read about drugs in development for osteoarthritis, the JAK-STAT pathway as a therapeutic target, novel drugs for schizophrenia, CAR T cell therapies for autoimmune diseases and more here
www.nature.com/nrd/volumes/...
about 1 month ago
1
0
0
The PI3K pathway has key roles in cancer, immune regulation and genetic disorders. This Perspective discusses advances in understanding of PI3K signalling in disease and novel pharmacological strategies to target the pathway
rdcu.be/faYxr
www.nature.com/articles/s41...
about 1 month ago
0
6
3
For readers interested in lipid nanoparticles for oligonucleotide delivery, here's an article covering 60 years of progress in the field
rdcu.be/fb9xD
nature.com/articles/s41...
about 1 month ago
0
2
2
Our latest research highlight covers a paper in Nature on the design of lipid nanoparticles for delivery of mRNA to the pancreas
nature.com/articles/d41...
about 1 month ago
0
0
0
For readers interested in GLP-1-based therapies for obesity and beyond, here's a comprehensive review
www.nature.com/articles/s41...
rdcu.be/fbrIE
about 1 month ago
1
4
2
FDA approves GLP-1 pill for obesity
nature.com/articles/d41...
Eli Lillyâs orforglipron is the first small-molecule GLP-1 receptor agonist to secure approval, offering a potential convenience edge over established peptidic GLP-1-based obesity drugs
about 1 month ago
0
1
0
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs
www.nature.com/articles/s41...
rdcu.be/fbphx
This new Review discusses how formulations can address delivery challenges for novel therapeutic modalities such as PROTACs and cyclic peptides
loading . . .
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs - Nature Reviews Drug Discovery
The oral delivery of small-molecule drugs with poor aqueous solubility represents an ongoing drug development challenge. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) have eme...
https://www.nature.com/articles/s41573-026-01407-5
about 1 month ago
0
0
0
For readers interested in drug discovery for fibrotic diseases, here's a review on cross-organ biology and pathways to development of innovative drugs
www.nature.com/articles/s41...
rdcu.be/fbcDC
about 2 months ago
0
1
0
Our latest research highlight covers a paper in Cell identifying ROCK2 as a target for liver fibrosis and reporting an early-stage clinical trial of a selective ROCK2 inhibitor
www.nature.com/articles/d41...
loading . . .
ROCK2 is a druggable angiocrine target in liver fibrosis
Discover the worldâs best science and medicine | Nature.com
https://www.nature.com/articles/d41573-026-00053-1
about 2 months ago
0
0
0
A renaissance in targeting the PI3K/AKT/mTOR pathway
www.nature.com/articles/s41...
rdcu.be/faYxr
This new Perspective discusses how advances in understanding of PI3K signalling in disease and novel pharmacological strategies are revitalizing interest in targeting the pathway
about 2 months ago
0
2
2
For readers interested in novel drugs for chronic obstructive pulmonary disease, such as AstraZeneca's IL-33 inhibitor tozorakimab, here's a recent review
www.nature.com/articles/s41...
rdcu.be/faMN3
about 2 months ago
0
1
0
reposted by
Nature Reviews Drug Discovery
Endpoints News
about 2 months ago
AstraZenecaâs COPD antibody gets Phase 3 wins in broader-than-expected population.
endpoints.news/astrazenecas...
loading . . .
AstraZenecaâs COPD antibody gets Phase 3 wins in broader-than-expected population
AstraZeneca's tozorakimab succeeds in two Phase 3 COPD trials, showing efficacy in broad patient populations despite earlier Phase 2 failure. Data details pending.
https://endpoints.news/astrazenecas-copd-antibody-gets-phase-3-wins-in-broader-than-expected-population/?utm_source=Bluesky&utm_medium=organic_social&utm_campaign=editorial&utm_content=
0
2
2
First-in-class bloodâbrain barrier shuttle wins FDA nod for Hunter syndrome
www.nature.com/articles/d41...
Denali Therapeuticsâ tividenofusp alfa - an enzyme fused to a bloodâbrain barrier-penetrating Fc domain - showcases an emerging approach to better get complex drugs into the brain
about 2 months ago
0
0
0
The therapeutic potential of orphan adhesion G-protein-coupled receptors
nature.com/articles/s41...
rdcu.be/e52UX
This Review discusses opportunities to target adhesion GPCRs in cancer, psychiatric disorders and autoimmune diseases, based on advances in structural biology
about 2 months ago
0
0
1
Wearable technologies in clinical trials for drug development: trends and emerging opportunities
rdcu.be/e9L7x
www.nature.com/articles/s41...
This new Review summarizes the characteristics of classes of wearable technologies, and analyses their use in drug trials and the regulatory landscape
loading . . .
Wearable technologies in clinical trials for drug development: trends and emerging opportunities
Nature Reviews Drug Discovery - Wearable technologies, which provide new tools to capture physiological and behavioural endpoints in real-world settings, are increasingly being integrated into...
https://rdcu.be/e9L7x
about 2 months ago
0
0
1
Can a first disease-modifying osteoarthritis drug make it past the FDA?
www.nature.com/articles/d41...
Biosplice says its dual CLK and DYRK kinase inhibitor reduces pain and slows joint damage. Up and coming localized gene therapies have the same goal
about 2 months ago
1
1
1
Alex Eccleston, Senior Editor at Nature Reviews Drug Discovery, will be attending the SMR conference âTarget To Patient 2026â on 20-21 April
www.smr.org.uk/Meetings/202...
@socmedres.bsky.social
about 2 months ago
0
1
2
Load more
feeds!
log in